Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2865053 | 0.97 | NFKB1 (0.45) | NFKB1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL14041742 | 0.87 | APP (0.59) | ALDH1A1KDM4ELMNASMN1; SMN2TYR | |
| SCHEMBL14188112 | 0.87 | APP (0.59) | NFKB1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL9320342 | 0.83 | ESR1 (0.48) | NFKB1TSHRALDH1A1MAPTKIF11 | |
| SCHEMBL23711025 | 0.80 | TSHR (0.64) | NFKB1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL29950147 | 0.80 | NFKB1 (0.59) | NFKB1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL28833363 | 0.80 | ALDH1A1 (0.48) | NFKB1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL2495683 | 0.80 | TSHR (0.48) | TSHRALDH1A1MAPTKIF11HPGD | |
| SCHEMBL3958499 | 0.80 | NFKB1 (0.59) | NFKB1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL24017762 | 0.79 | NOS3 (0.42) | NFKB1TSHRALDH1A1KIF11HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113600190-B | Copper (II) -doped carbon nanotube material and preparation method and application thereof | 浙江工业大学 | 2025-01-07 | — | — | CN | claimed |
| CN-117886718-B | Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound | 内蒙古工业大学 | 2024-05-24 | — | — | CN | claimed |
| CN-117886718-A | Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound | 内蒙古工业大学 | 2024-04-16 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| CN-109678852-A | 6- oxo hexahydropyrimidine derivative, preparation method and pharmacy application | 南京中医药大学 | 2019-04-26 | — | — | CN | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | claimed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | claimed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | claimed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | claimed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | claimed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | claimed |
| CN-113600190-B | Copper (II) -doped carbon nanotube material and preparation method and application thereof | 浙江工业大学 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024112123-A1 | NOVEL COMPOUND AS SELECTIVE ESTROGEN RECEPTOR MODULATOR | 재단법인 대구경북첨단의료산업진흥재단 | 2024-05-30 | — | — | WO | disclosed |
| CN-117886718-B | Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound | 内蒙古工业大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-117886718-A | Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound | 内蒙古工业大学 | 2024-04-16 | — | — | CN | disclosed |
| EP-0321275-A2 | Preparation of anilines | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-21 | — | — | EP | disclosed |
| EP-0293483-A1 | PROCESS FOR PREPARING ANILINES, CATALYST THEREFOR, AND PROCESS FOR PREPARING THE CATALYST | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-12-07 | — | — | EP | disclosed |
| US-4558101-A | FROM HYDROCARBON POLYMER CONTAINING OLEFINIC GROUPS WITH HYDROGEN CARBON MONOXIDE AND AMINE USING GROUP 8 METAL CATALYST | W. R. GRACE & CO. (US) | 1985-12-10 | — | — | US | disclosed |
| US-4526936-A | Reacting polymeric hydrocarbon, primary or secondary amine, carbon monoxide, hydrogen, in the presence of group VIII metal catalyst | W. R. GRACE & CO. (US) | 1985-07-02 | — | — | US | disclosed |
| US-4312965-A | Process for forming amine/amide containing polymers | W. R. GRACE & CO. (US) | 1982-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | NFKB1 1886/4885TSHR 2316/4885ALDH1A1 401/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | NFKB1 2479/4885TSHR 1299/4885ALDH1A1 262/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | NFKB1 2718/4885TSHR 1178/4885ALDH1A1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.